Zenas BioPharma Reports Positive Phase 3 Obexelimab Results in IgG4-RD
WALTHAM, Mass., June 2, 2026 Zenas BioPharma, Inc. announced positive results from its registrational Phase 3 INDIGO trial evaluating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WALTHAM, Mass., June 2, 2026 Zenas BioPharma, Inc. announced positive results from its registrational Phase 3 INDIGO trial evaluating...
